文献速递淋巴瘤

选择性抑制核输出蛋白XPO1药物selinexor治疗非霍奇金淋巴瘤患者

Selective inhibition of nuclear export with selinexor in patients with non-Hodgkin lymphoma.
PubMed 文献 · Blood · 2017-05-03

这项1期试验纳入79例复发或难治性非霍奇金淋巴瘤患者,评估口服XPO1抑制剂selinexor的安全性和2期推荐剂量。剂量递增阶段给予3至80 mg/m2,剂量扩展阶段给予35或60 mg/m2;最常见3至4级药物相关不良事件为血小板减少(47%)、中性粒细胞减少(32%)和贫血(27%)。70例可评估患者中22例(31%)客观缓解,确定2期推荐剂量为35 mg/m2(60 mg)。

要点

  • selinexor在复发或难治性非霍奇金淋巴瘤中客观缓解率为31%(22/70),含4例完全缓解和18例部分缓解。
  • 最常见3至4级药物相关不良事件为血小板减少47%、中性粒细胞减少32%、贫血27%。
  • 2期推荐剂量为35 mg/m2(60 mg),口服给药。

核心结论

  • 口服selinexor 35 mg/m2抑制XPO1在复发或难治性非霍奇金淋巴瘤患者中是一种安全疗法,并具有令人鼓舞且持久的抗癌活性。

研究设计与样本

  • 这项1期试验纳入79例各种组织学类型的非霍奇金淋巴瘤患者,包括弥漫大B细胞淋巴瘤、Richter转化、套细胞淋巴瘤、滤泡性淋巴瘤和慢性淋巴细胞白血病。
  • 剂量递增阶段患者接受3至80 mg/m2 selinexor,以3周或4周为周期,评估毒性、药代动力学和抗肿瘤活性。
  • 剂量扩展阶段患者接受selinexor 35或60 mg/m2治疗。
  • 试验注册号为NCT01607892。

主要发现

  • 最常见3至4级药物相关不良事件为血小板减少(47%)、中性粒细胞减少(32%)、贫血(27%)、白细胞减少(16%)、疲乏(11%)和低钠血症(10%)。
  • 肿瘤活检显示治疗后细胞信号通路(Bcl-2、Bcl-6、c-Myc)下降、增殖(Ki67)减少、XPO1货物蛋白(p53、PTEN)核定位及凋亡增加。
  • 70例可评估患者中22例(31%)达到客观缓解,包括4例完全缓解和18例部分缓解,缓解见于多种非霍奇金淋巴瘤亚型。
  • 确定2期推荐剂量为35 mg/m2(60 mg)。

关键数值与推荐

  • 2期推荐剂量为selinexor 35 mg/m2(60 mg)。
  • 剂量递增阶段selinexor剂量范围为3至80 mg/m2,以3周或4周为周期给药。
  • 剂量扩展阶段selinexor剂量为35或60 mg/m2。

临床怎么用

  • 作者认为口服selinexor 35 mg/m2抑制XPO1是复发或难治性非霍奇金淋巴瘤患者的一种安全疗法,具有令人鼓舞且持久的抗癌活性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Patients with relapsed or refractory (R/R) non-Hodgkin lymphoma (NHL) have a poor prognosis and limited treatment options. We evaluated selinexor, an orally bioavailable, first-in-class inhibitor of the nuclear export protein XPO1, in this phase 1 trial to assess safety and determine a recommended phase 2 dose (RP2D). Seventy-nine patients with various NHL histologies, including diffuse large B-cell lymphoma, Richter's transformation, mantle cell lymphoma, follicular lymphoma, and chronic lymphocytic leukemia, were enrolled. In the dose-escalation phase, patients received 3 to 80 mg/m2 of selinexor in 3- or 4-week cycles and were assessed for toxicities, pharmacokinetics, and antitumor activity. In the dose-expansion phase, patients were treated with selinexor at 35 or 60 mg/m2 The most common grade 3 to 4 drug-related adverse events were thrombocytopenia (47%), neutropenia (32%), anemia (27%), leukopenia (16%), fatigue (11%), and hyponatremia (10%). Tumor biopsies showed decreases in cell-signaling pathways (Bcl-2, Bcl-6, c-Myc), reduced proliferation (Ki67), nuclear localization of XPO1 cargos (p53, PTEN), and increased apoptosis after treatment. Twenty-two (31%) of the 70 evaluable patients had an objective responses, including 4 complete responses and 18 partial responses, which were observed across a spectrum of NHL subtypes. A dose of 35 mg/m2 (60 mg) was identified as the RP2D. These findings suggest that inhibition of XPO1 with oral selinexor at 35 mg/m2 is a safe therapy with encouraging and durable anticancer activity in patients with R/R NHL. The trial was registered at www.clinicaltrials.gov as #NCT01607892.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Kuruvilla J, Savona M, Baz R, et al. Selective inhibition of nuclear export with selinexor in patients with non-Hodgkin lymphoma. Blood. 2017. PMID: 28468797. doi:10.1182/blood-2016-11-750174

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。